Cumberland will promote its drug portfolio to Apotex for $100 million
Cumberland Prescribed drugs has agreed to promote its business branded drug portfolio to Canadian pharmaceutical firm Apotex for $100 million in money.
Beneath the settlement, Apotex will purchase Cumberland’s branded prescribed drugs for money, topic to approval by Cumberland’s shareholders.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
The partnership goals to ascertain a sturdy specialty medicines platform within the US.
Cumberland will retain possession of its pipeline product candidates and a majority stake in Cumberland Rising Applied sciences.
Following the transaction, the corporate plans to give attention to creating these pipeline merchandise to capitalize on important market alternatives.
Cumberland Prescribed drugs CEO A Kazimi mentioned: “Our firm has two distinct profiles: with established business operations typical of a specialty pharmaceutical firm and an thrilling improvement pipeline typically related to a biotechnology firm.
“This transaction unlocks worth for our shareholders and permits us to give attention to the big market alternatives related to our pipeline product candidates.
“We consider the combination of those merchandise with Apotex will create extra important mass to help affected person care and supply higher profession alternatives for our business workforce.”
Apotex President and CEO Jeff Watson mentioned: “This transaction will strengthen our potential to help sufferers at a few of the most crucial moments of their care journey.
“Integrating Cumberland’s business operations into the Apotex household will improve our potential to ship significant well being impression to sufferers within the US.”
In its present pipeline, Cumberland is creating ifetroban, a thromboxane antagonist, via a number of medical applications.
Groundbreaking outcomes have been lately introduced in a Section II trial for cardiomyopathy related to Duchenne muscular dystrophy, with ongoing interactions with the US Meals and Drug Administration (FDA).
The ifetroban program contains orphan medicine, uncommon pediatric ailments and quick monitor statuses.
Cumberland additionally has ongoing Section II medical trials for ifetroban in systemic sclerosis and idiopathic pulmonary fibrosis, with remaining enrollments and interim examine outcomes pending.
In February 2025, Cumberland Prescribed drugs’ injection antibiotic Vibativ (telavancin) acquired approval from China’s Nationwide Medical Merchandise Administration (NMPA), offering a brand new remedy possibility for sufferers with severe bacterial infections.
